Bulletin
Investor Alert

New York Markets Close in:

Market Pulse Archives

Sept. 21, 2020, 7:08 a.m. EDT

Illumina's stock falls after $8 billion deal to buy Grail confirmed

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Illumina Inc. (ILMN)
  • X
    iShares Nasdaq Biotechnology ETF (IBB)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Illumina Inc. /zigman2/quotes/203509482/composite ILMN -5.97% dropped 5.3% in premarket trading Monday, after the gene sequencing company confirmed a deal to buy Grail Inc. for $8 billion in cash and stock. The Wall Street Journal reported earlier that an announcement of the deal, in which Illumina pays $7.1 billion for the part of Grail it doesn't already own, would be announced Monday. The report said the deal for the developer of a blood test that helps detect cancer, is expected to be announced Monday. Illumina said the deal includes $3.5 billion in cash and $4.5 billion in Illumina shares. "GRAIL extends Illumina's portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas," Illumina said in a statement. The stock has dropped 10.9% year to date through Friday, while the iShares Nasdaq Biotechnology ETF /zigman2/quotes/206189322/composite IBB -2.22% has rallied 13.1% and the S&P 500 /zigman2/quotes/210599714/realtime SPX -1.54% has gained 2.8%.

/zigman2/quotes/203509482/composite
US : U.S.: Nasdaq
$ 296.09
-18.81 -5.97%
Volume: 1.25M
Oct. 30, 2020 12:51p
P/E Ratio
63.94
Dividend Yield
N/A
Market Cap
$46.09 billion
Rev. per Employee
$456,575
loading...
/zigman2/quotes/206189322/composite
US : U.S.: Nasdaq
$ 130.10
-2.96 -2.22%
Volume: 1.75M
Oct. 30, 2020 12:51p
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,259.14
-50.97 -1.54%
Volume: 1.26B
Oct. 30, 2020 12:51p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.